Corrected -- CoMeD Presentation to WHO

[Guest guest]

All,

Please use the following text instead of the original because

the original contained some typographical errors  that have

been corrected and was missing a part of the statement on the

metabolism of ethylmercury species in humans.

This e-mail is to alert you that Dr. King presented his formal

remarks to the WHO Listening session on the update of the WHO

position on mercury (Thimerosal) in vaccines and other drugs

that was held on 3 April 2012 in Geneva, Switzerland at 9:00 -

10:23 AM (Geneva time), which can be found

here

http://dr-king.com/docs/20120331_FalsusInUnoFalsusInOmnibusAThimerosalpreservedVaccineConundrum_b.pdf

In addition to his formal written

comments titled, "'Falsus in unum, Falsus in omnibus' -- The

Thimerosal-preserved Vaccine Conundrum", Dr. King remarks

also addressed:

 

Who

AM I? 

G. King, PhD Analytical Chemist with an MS in

Inorganic Chemistry and 12+ years of study on

Thimerosal, vaccines, vaccination programs, and

the issues surrounding them.

 

Recent

WHO History “the Swine Flu pandemic of 2009-2010 –

a false warning for a disease for which the

vaccines are not in-use effective.

 

The

LACK of Toxicity data proving safety – No Observed

Adverse Effects Level (NOAEL) for injected

Thimerosal in developing children from conception

onwards.

 

Pichichero

studies – fatally flawed – they do not

measure clearance from the body! Only

from the blood! 

[studies

by Japanese using radiolabeled 203Hg have shown

<< 15% excreted in urine and feces in short

period of time after  inoculation.  A 10-fold

toxicity difference has been verified using

radiolabeled Hg in rats and monkeys where for the same

specific dose (0.8 mcg/g) the Hg levels in the rat and

monkey kidney at sacrifice (up to 8days after

exposure) were about the same but the level in the

monkey’s brain was about 10+ X of that in the rat and

higher (about 1.2 mcg/g) than the initial dosing level

0.8 mcg/g]  {Note: "mcg" is the abbreviation for

"microgram"}

 

2008

study showed presence of ethyl, methyl and

inorganic mercury when blood was speciated (methyl

attributed to some unknown source) but this

explanation is not consistent with what is known

about “metabolism” of Thimerosal in humans:

ethylmercury species ==> methylmercury species

==> tissue-retained inorganic mercury (II)

species.

 

FDA’s

statements are, at best, misleading [Dr. Ball’s

slides]:

a.       On page 7: statements

are

misleading, at best, because the licenses for the

2-PE-preserved vaccines have not been revoked

allowing manufacturers to continue to make them

for other markets – just as the licenses for the

Thimerosal-preserved and reduced-Thimerosal

vaccine formulations have not been revoked.

b.       On

page 9:

“Alternative

to Thimerosal Preservative (cont.)

Thimerosal

preservative containing vaccines have been

proven safe under the applicable statutory and

regulatory requirements  --

this statement is false

Substituting

thimerosal preservative in currently licensed

vaccines has the potential to modify the stability,

safety and effectiveness of these vaccines"

c.       

On page 10:

“Alternative to

Thimerosal Preservative (cont.)

21 CFR Section

610.15(a) provides: All ingredients used in a licensed

product, …, shall meet generally accepted standards of

purity and quality. Any preservative used shall be sufficiently

nontoxic so that the amount present in the

recommended dose of the product will not be toxic to

the recipient. . .

FDA evaluates

whether a preservative contained in a biological

product is at such levels that the finished product

itself, when used at the recommended dose, is not

toxic to the recipient  [Where are the

FDA’s NOAEL values???]

Preservatives are

not examined in isolation, rather, 21 CFR 610.15(a)

specifically directs that preservatives be examined in

the context of the overall product and the recommended

dose” 

[My

problems with the preceding assertions:

A.    

The vaccine

maker, and NOT the FDA, has an absolute,

nondischargeable duty to prove the safety to

whatever standards that are established under the

applicable current good manufacturing practice

(CGMP) regulations.

B.    

To

establish that a compound used as a preservative is

nontoxic – vaccine maker has, since 1968, been

required to prove that the level of Thimerosal in

the vaccine dose is below the NOAEL for injected

Thimerosal in the developing child.

C.       To

establish that Thimerosal is sufficiently nontoxic,

the vaccine must prove that the highest level of

Thimerosal possible in a dose is below the NOAEL for

injected vaccine containing Thimerosal by some

safety factor – which, for bioaccumulative toxicants

like Thimerosal, must be at least a factor of 10

below that NOAEL.

D.    

Since 1977,

the FDA has been required to only license vaccines

that meet all of their requirements including 21 CFR

Sec. 6210.15(a) for Thimerosal in a

Thimerosal-preserved vaccine (21 CFR Sec 601.4(a)).

E.    

Since 1999, the

vaccine makers have been required to submit proof of

compliance with all applicable CGMP requirements to the

FDA.

F.    

In

2003, a Congressional report, "Mercury in Medicine –

Taking Unnecessary Risks", established that, for

Thimerosal-preserved vaccines, the vaccine makers had

failed to comply with 21 CFR Sec. 610.15(a) and the FDA

had failed to comply with 21 CFR Sec. 601.4(a).]

as well as the biased search and

review of the new literature on Thimerosal, vaccines and

autism from 2008 to early 2012, which appeared to miss >

100 applicable articles and, perhaps, > 900 of them.

Hopefully, all will verify the validity of the preceding for

themselves.

Regards,

Dr. King